Anna Angelousi
Overview
Explore the profile of Anna Angelousi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Angelousi A, Alexandraki K, Mytareli C, Grossman A, Kaltsas G
J Neuroendocrinol
. 2023 Jan;
35(1):e13233.
PMID: 36683321
Diabetes insipidus (DI) is a disorder characterised by the excretion of large amounts of hypotonic urine, with a prevalence of 1 per 25,000 population. Central DI (CDI), better now referred...
22.
Angelousi A, Koumarianou A, Chatzellis E, Kaltsas G
Expert Rev Endocrinol Metab
. 2023 Jan;
18(1):33-52.
PMID: 36651768
Introduction: A common feature shared by most neuroendocrine tumors (NETs) is the expression on their surface of somatostatin receptors (SSTRs) that are essential for their pathophysiological regulation, diagnosis, and management....
23.
Angelousi A, Papalexis P, Karampela A, Marra M, Misthos D, Ziogas D, et al.
Exp Ther Med
. 2022 Dec;
25(1):10.
PMID: 36561623
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (PD-1), anti-programmed cell death protein ligand 1 (PD-L1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibodies, are novel therapeutic agents...
24.
Stefanidis P, Kyriakopoulos G, Seretis A, Korfias S, Theocharis S, Angelousi A
Diagnostics (Basel)
. 2022 Oct;
12(10).
PMID: 36292101
(1) Background: The aim of the current study is to evaluate the immunohistochemical expression of Ki-67, CD-56, Cyclin-D1 and E-Cadherin in the tissues samples of pituitary adenomas (PAs) and its...
25.
Angelousi A, Hayes A, Chatzellis E, Kaltsas G, Grossman A
Endocr Relat Cancer
. 2022 May;
29(7):R85-R103.
PMID: 35521769
Medullary thyroid carcinoma (MTC) is a rare malignancy comprising 1-2% of all thyroid cancers in the United States. Approximately 20% of cases are familial, secondary to a germline RET mutation,...
26.
Stefanidis P, Kyriakopoulos G, Athanasouli F, Mytareli C, Tzanis G, Korfias S, et al.
Hormones (Athens)
. 2022 Apr;
21(2):345.
PMID: 35426032
No abstract available.
27.
Stefanidis P, Kyriakopoulos G, Athanasouli F, Mytareli C, Tzanis G, Korfias S, et al.
Hormones (Athens)
. 2022 Mar;
21(3):487-499.
PMID: 35277844
Purpose: Endoscope-assisted transsphenoidal surgery over the last few years has led to more radical excision of pituitary adenomas (PAs) with a low complication rate. Systematic registration of complications by experienced...
28.
Mytareli C, Delivanis D, Athanassouli F, Kalotychou V, Mantzourani M, Kassi E, et al.
Biomedicines
. 2021 Nov;
9(11).
PMID: 34829730
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a dismal prognosis and a high rate of recurrence and mortality. Therapeutic options are limited. In some cases, the distinction of...
29.
Parianos C, Kyriakopoulos G, Kostakis I, Nasiri-Ansari N, Aggeli C, Dimitriadi A, et al.
Horm Metab Res
. 2021 Nov;
53(11):709-716.
PMID: 34740271
Adrenocortical carcinoma (ACC) is a rare but very aggressive endocrine malignancy with poor survival. Histopathology is important for diagnosis, while in some cases immunohistochemical markers and gene profiling of the...
30.
Gkoufa A, Angelousi A, Neonaki A, Athanasouli F, Cholongitas E
Ann Pharmacother
. 2021 Oct;
56(7):853-855.
PMID: 34697948
No abstract available.